about
Tackling ALK in non-small cell lung cancer: the role of novel inhibitorsCellular and molecular biology of small cell lung cancer: an overviewIntegrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicityPlatelets and their role in cancer evolution and immune systemMelanoma: oncogenic drivers and the immune systemDeciphering Crosstalk Circuits in Non-small Cell Lung Cancers with an Increasing Interval Length of Low Dose CT ScreeningDifferential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancerMetastatic pancreatic cancer: Is there a light at the end of the tunnel?Extra-nodal extension of sentinel lymph node metastasis is a marker of poor prognosis in breast cancer patients: A systematic review and an exploratory meta-analysis.Clinical results of randomized trials and 'real-world' data exploring the impact of Bevacizumab for breast cancer: opportunities for clinical practice and perspectives for research.A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients.Fixed dose-rate gemcitabine infusion as first-line treatment for advanced-stage carcinoma of the pancreas and biliary tree.Antiblastic chemotherapy in the presence of abdominal aorta aneurysm (AAA): guidelines.Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: meta-analysis of randomized trials.Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trialsGuideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference.Malignant bronchial Abrikossoff's tumor and small cell lung cancer: a case report and review.True 3q chromosomal amplification in squamous cell lung carcinoma by FISH and aCGH molecular analysis: impact on targeted drugsBrain metastases from solid tumors: disease outcome according to type of treatment and therapeutic resources of the treating centerPrognostic impact of alternative splicing-derived hMENA isoforms in resected, node-negative, non-small-cell lung cancer.Maintenance therapy in NSCLC: why? To whom? Which agent?Molecular typing of lung adenocarcinoma on cytological samples using a multigene next generation sequencing panel.Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials.Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysis.Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis.Prognostic Value of Beta-Tubulin-3 and c-Myc in Muscle Invasive Urothelial Carcinoma of the Bladder.The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer.Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma.Weekly docetaxel in pretreated metastatic breast cancer patients: a phase I-II study.New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials.BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancerNon-small cell lung cancer: early stages.Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer.FGFR-1 amplification in metastatic lymph-nodal and haematogenous lobular breast carcinoma.Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials.Comprehensive molecular portrait using next generation sequencing of resected intestinal-type gastric cancer patients dichotomized according to prognosis.Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant SettingSubpopulation Treatment Effect Pattern Plot (STEPP) analysis of Ki67 assay according to histology: prognostic relevance for resected early stage 'pure' and 'mixed' lobular breast cancer.Aromatase inhibitors in post-menopausal metastatic breast carcinoma.
P50
Q26740329-A7167729-2DC4-41AC-BC4E-D802CEB348BCQ26767029-1EB9EC77-7513-4061-B6BC-96C25E5D8077Q26769744-DDCAEF1C-1377-48AC-A9BF-83B71CE285DDQ26769754-46FF2AFF-1E85-4EE0-9B87-75CAC32D6043Q26775598-39238B6A-A51C-4B69-9C3C-274FA70627ACQ26783155-148D2303-0BE5-468D-AD45-6B3A289D0AFAQ27853176-1F6B69E0-BF84-4C94-8528-C2C7F7009938Q28072004-D786AFA6-29FE-4F25-A694-3FFECCFBCCB1Q28082919-EF886B7A-83A5-463F-BF5F-A4DD0F4562D5Q30251731-F0EBF2B2-2F81-4F6C-9F30-AE01C88386B3Q31157714-446968EE-0637-4959-B358-71ED2C439112Q33357544-26E5A63D-17B8-41D0-A382-5823F286052AQ33367641-5143DB4E-E49C-4FA0-B6BF-54F7D93000DFQ33655367-ABB66F64-502F-4FE8-AC81-28549A1170FFQ33766974-672EE71E-926F-46E6-B282-992AAF43F200Q33933669-30217F5D-CCCF-4129-B1CF-5C96D38ECD9FQ34121232-62BD2DBB-6F37-4B68-BC05-9AE0B9235753Q34217092-C49DCED5-E063-4093-8C8D-48438CA6DFD5Q34510256-1D32251A-4800-4B18-9F56-75B69BFACBEFQ34552757-5BF0A522-F65D-411A-8B15-225FA9A3B3F0Q34957141-FB1D39B9-D25F-4832-BB9B-AF6A2E3461C5Q35041521-95ABB4A3-2651-4768-805B-83B910B86F16Q35043965-EB7B03E7-BACE-491D-890F-18569E81853FQ35061280-465EDE90-B643-4B36-84F0-E5CBE09B7C48Q35241042-947CA682-07FA-4E81-85FA-C0E6FF288D30Q35450437-21838BA8-6DAB-4F08-AB92-E0AF414B0564Q35653741-586310F9-E171-446A-A294-53EFCDE111CFQ35764604-49FC5FE6-E79E-4406-B8AF-8D9ACF59B510Q35828688-81DDC137-459A-483A-85BC-7BE731CDA411Q36195479-ADF9D1A5-4737-4E7B-AAD1-4D235A8643E9Q36223219-0A37FE8A-58C0-4BF8-A739-7D556255BC70Q36350128-8A6C8AC2-DA73-4D58-B6CB-C1C441CDB5F8Q36445793-386B5BB7-9E4D-4D00-B317-5CFCC5A5AD76Q36472959-8A7DCFD6-A05D-4BFB-83F0-5D9E34221E2BQ36524946-A823E875-4ACC-4D29-9001-FF146472618EQ36614435-5E78BA5C-88FE-4C75-958F-8F609D877089Q36670779-11C07A67-682A-4330-A012-F56172177A24Q36673469-1CBFC8FC-96DA-4B49-B8AB-5905D0C7EBE6Q36715181-0385CA08-0879-4D91-B1C2-831641D5D7D2Q36861597-EDFACBD5-283C-4E4C-BA22-5941B41C83FC
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Emilio Bria
@ast
Emilio Bria
@en
Emilio Bria
@es
Emilio Bria
@nl
Emilio Bria
@sl
type
label
Emilio Bria
@ast
Emilio Bria
@en
Emilio Bria
@es
Emilio Bria
@nl
Emilio Bria
@sl
prefLabel
Emilio Bria
@ast
Emilio Bria
@en
Emilio Bria
@es
Emilio Bria
@nl
Emilio Bria
@sl
P106
P1153
6603264129
P21
P31
P496
0000-0002-2333-704X